Shah, Bijal
Chen, Jenny M. H.
Wu, James J.
Feng, Chaoling
Zhou, Lang
Park, Julie E.
Hadjiivassileva, Tsveta
Kerbauy, Fabio R.
Wade, Sally W.
Keeping, Sam
Funding for this research was provided by:
Kite Pharma
Article History
Received: 11 July 2023
Accepted: 22 August 2023
First Online: 6 October 2023
Declarations
:
: Bijal Shah has received consultant and education fees from Amgen, Pfizer, Novartis, BMS/Celgene/Juno, Kite, a Gilead company, Precision Biosciences, Jazz, Beigene, Adaptive, Century Therapeutics, and Autolus; and clinical trial grants from Kite, a Gilead company, Jazz, and Servier. Jenny M.H. Chen, Julie E. Park, and Sam Keeping are employees of PRECISIONheor, funded by Kite, a Gilead Company for this study. James J. Wu is an employee of Kite, a Gilead Company; has received honoraria from the Patient-Centered Outcomes Research Institute (PCORI), both as a member of the Rare Disease Advisory Panel, and as a grants reviewer for the Improving Methods Program; has received travel/meeting support from Kite, a Gilead Company, and Amgen; owns stock in Gilead Sciences, Amgen, Abbott, AbbVie, Pfizer, Roche, Curis, Avid Biosciences, Evofem, Lensar, VBI Vaccines, and Viracta Therapeutics. Chaoling Feng is an employee of Kite, a Gilead Company and owns stock in Gilead Sciences. Lang Zhou is an employee of Kite, a Gilead Company and owns stock in AbbVie and Gilead Sciences. Tsveta Hadjiivassileva is an employee of Kite, a Gilead Company and owns stock in Gilead Sciences. Sally W. Wade has received consulting fees from Kite, a Gilead Company, Abbvie, and Johnson & Johnson. Fabio R. Kerbauy declares no competing interests.
: Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved the ZUMA-3, INO-VATE, and TOWER trials.